Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

Breast Cancer Research and Treatment

Volumn 108, Issue 2, 2008, Pages 289-296

  Byrski, T ^a   Gronwald, J ^a   Huzarski, T ^a   Grzybowska, E ^b   Budryk, M ^b   Stawicka, M ^c   Mierzwa, T ^d   Szwiec, M ^e   Wisniowski R ^f   Siolek, M ^g   Narod, S A ^h   Lubinski, J ^a   Foszczynska Kloda, M ⁱ   Serrano Fernandez P ⁱ   Chosia, M ⁱ   Ucinski M ⁱ   Lange, D ⁱ   Mika, B ⁱ   Mackiewicz, A ⁱ   Karczewska, A ⁱ   Breborowicz, J ⁱ   Lamperska, K ⁱ   Gozdecka Grodecka, S ⁱ   Bebenek M ⁱ   Sorokin, D ⁱ   Wojnar, A ⁱ   Haus, O ⁱ   Sir, J ⁱ   Niepsuj, S ⁱ   Gugala K ⁱ   Gozdz S ⁱ   Sygut, J ⁱ   Kozak Klonowska, B ⁱ   Musiatowicz, M ⁱ   Posmyk, R ⁱ   Kordek, M ⁱ   Morawiec, O ⁱ   Zambrano, B ⁱ   Wasko L ⁱ   Fudali, D ⁱ   Surdynka, D ⁱ   Urbanski K ⁱ   Mitus J ⁱ   Rys J ⁱ   Rozmiarek, A ⁱ   Dziuba, I ⁱ   Wandzel, P ⁱ   Szczylik, C ⁱ   Kozak, A ⁱ   Kozlowski A ⁱ   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c Prophylactic and Epidemiology Center   (Poland)

^d Regional Oncology Hospital   (Poland)

^e Regional Oncology Center   (Poland)

^f Oncologic Hospital   (Poland)

^g Holycross Cancer Center   (Poland)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ NONE

Author keywords

BRCA1; Breast cancer; Doxorubicin; Neo adjuvant chemotherapy; Taxane

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PREDNISONE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PATIENT SELECTION; POLAND; REGISTRIES; TAXOIDS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 39749119151     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9600-1     Document Type: Article

References (24)

1. Marcus JN, Watson P, Page DL et al (1997) BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 44:275-277
2. Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138-1145
3. Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830-835
4. Johannsson OT, Idvall I, Anderson C et al (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33:362-371
5. Moynahan ME, Cui TY, Jasin M (2001) Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res 61:4842-4850
6. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899-23903
7. Fedier A, Steiner RA, Schwartz VA et al (2003) The effect of loss of Brca1 on the sensitivity of anticancer agents in p53-deficient cells. Int J Oncol 22:1169-1173
8. Chabalier C, Lamare C, Racca C et al (2003) BRCA1 down-regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5:1001-1007
9. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
10. Lubinski J, Gorski B, Huzarski T et al (2006) BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99:71-76
11. Górski B, Byrski T, Huzarski T et al (2000) Founder mutations in BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 66:1963-1968
12. Górski B, Jakubowska A, Huzarski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683-686
13. Kennedy RD, Quinn JE, Mullan PB et al (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659-1668
14. Zhoue C, Smith JL, Lui J (2003) Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22:2396-2404
15. Lafarge S, Sulvain V, Ferrara M, Bignon YJ (2001) Inhibition of BRCA1 leads to increased chemoresistance to micotubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20:6597-6606
16. Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a diferential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221-6228
17. Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285-1291
18. Chappuis PO, Goffin J, Wong N et al (2002) A significant response to neoadjuant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39:608-610
19. Delaloge S, Kloos I et al (2002) BRCA1-linked breast cancer is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Program and abstracts of the 27th Congress of the European Society for Medical Oncology 2002
20. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to pre-operative chemotherapy. Clin Cancer Res 11:5678-5685
21. Foulkes WD, Stefansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485
22. Kennedy RD, Quinn JR, Mullan PB, Johnston PG, Harkin DP (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659-1668
23. Turner N, Tutt A, Ashworth A (2005) Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5:338-393
24. Garber JE, Richardson A, Harris LN et al (2006) Neo-adjuvant cisplatin (CDPP) in "triple-negative" breast cancer. Abstract of the San Antonio Breast Cancer Symposium, San Antonio